Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.
作者信息
Collie Shirley, Champion Jared, Moultrie Harry, Bekker Linda-Gail, Gray Glenda
机构信息
Discovery Health, Johannesburg, South Africa.
National Institute of Communicable Diseases, Johannesburg, South Africa.
出版信息
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
Abstract
摘要
相似文献
1
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
2
Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.Ad26.COV2.S和BNT162b2疫苗在南非针对奥密克戎变种的有效性
N Engl J Med. 2022 Jun 9;386(23):2243-2245. doi: 10.1056/NEJMc2202061. Epub 2022 May 4.
3
Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.BNT162b2疫苗在南非针对奥密克戎亚谱系的有效性和持久性
N Engl J Med. 2022 Oct 6;387(14):1332-1333. doi: 10.1056/NEJMc2210093. Epub 2022 Sep 14.
4
BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years.BNT162b2疫苗对5至11岁儿童中SARS-CoV-2奥密克戎变异株的有效性
JAMA Pediatr. 2023 Mar 1;177(3):319-320. doi: 10.1001/jamapediatrics.2022.5221.
5
Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.随着时间的推移，科兴和国药疫苗对奥密克戎患者严重结局的疫苗有效性估计
JAMA Netw Open. 2023 Feb 1;6(2):e2254777. doi: 10.1001/jamanetworkopen.2022.54777.
6
Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.估计 BNT162b2 疫苗对美国 5 至 11 岁儿童感染德尔塔和奥密克戎变异株的有效性。
JAMA Netw Open. 2022 Dec 1;5(12):e2246915. doi: 10.1001/jamanetworkopen.2022.46915.
7
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.奥密克戎变异株疫苗有效性的系统评价和荟萃分析。
Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022.
8
BNT162b2 and mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved Population.BNT162b2和mRNA-1273疫苗对城市弱势群体中SARS-CoV-2及其变体的有效性
R I Med J (2013). 2023 Feb 1;106(1):26-28.
9
Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.BNT162b2 和科兴疫苗对香港有药物滥用史人群感染奥密克戎和相关住院的有效性：一项匹配病例对照研究。
Lancet Psychiatry. 2023 Jun;10(6):403-413. doi: 10.1016/S2215-0366(23)00111-6. Epub 2023 May 1.
10
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.疫苗对 Alpha、Delta 或奥密克戎变异株引起的 SARS-CoV-2 感染或 COVID-19 住院的有效性：一项全国性丹麦队列研究。
PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep.
引用本文的文献
1
SARS-CoV-2 vaccines elicit differential Fc effector functions.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗引发不同的Fc效应器功能。
iScience. 2025 Jul 9;28(8):113084. doi: 10.1016/j.isci.2025.113084. eCollection 2025 Aug 15.
2
Beyond COVID-19: the promise of next-generation coronavirus vaccines.超越新冠疫情：下一代冠状病毒疫苗的前景
Npj Viruses. 2024 Aug 22;2(1):39. doi: 10.1038/s44298-024-00043-3.
3
RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaques.去除RBD的新冠病毒刺突蛋白在食蟹猴中产生保护性免疫。
NPJ Vaccines. 2025 Mar 30;10(1):63. doi: 10.1038/s41541-025-01113-0.
4
Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.辉瑞-生物科技（BNT162b2）疫苗在50岁及以上成年人中针对新冠病毒奥密克戎变异株的有效性：2022年6月在黎巴嫩开展的一项病例对照研究
PLoS One. 2025 Mar 20;20(3):e0318344. doi: 10.1371/journal.pone.0318344. eCollection 2025.
5
Impact of COVID-19 vaccination on hospitalization, hospital utilization and expenditure for COVID-19: A retrospective cohort analysis of a South African private health insured population.新冠疫苗接种对新冠病毒感染住院情况、医院利用及支出的影响：一项针对南非有私人医疗保险人群的回顾性队列分析
PLoS One. 2025 Jan 24;20(1):e0317686. doi: 10.1371/journal.pone.0317686. eCollection 2025.
6
Case-only analysis of routine surveillance data: detection of increased vaccine breakthrough infections with SARS-CoV-2 variants in Europe.基于常规监测数据的病例对照分析：欧洲SARS-CoV-2变异株导致的疫苗突破性感染增加情况的检测
Epidemiol Infect. 2025 Jan 6;153:e16. doi: 10.1017/S0950268824001833.
7
CoronaVac-induced antibodies that facilitate Fc-mediated neutrophil phagocytosis track with COVID-19 disease resolution.科兴疫苗诱导的促进Fc介导的中性粒细胞吞噬作用的抗体与COVID-19疾病的缓解相关。
Emerg Microbes Infect. 2025 Dec;14(1):2434567. doi: 10.1080/22221751.2024.2434567. Epub 2025 Jan 13.
8
Viral N protein hijacks deaminase-containing RNA granules to enhance SARS-CoV-2 mutagenesis.病毒N蛋白劫持含脱氨酶的RNA颗粒以增强SARS-CoV-2的诱变作用。
EMBO J. 2024 Dec;43(24):6444-6468. doi: 10.1038/s44318-024-00314-y. Epub 2024 Nov 20.
9
Prospective clinical surveillance for severe acute respiratory illness and COVID-19 vaccine effectiveness in Kenyan hospitals during the COVID-19 pandemic.肯尼亚医院在 COVID-19 大流行期间对严重急性呼吸道疾病和 COVID-19 疫苗有效性的前瞻性临床监测。
BMC Infect Dis. 2024 Nov 5;24(1):1246. doi: 10.1186/s12879-024-10140-6.
10
Utility of ISARIC 4C Mortality Score, Vaccination History, and Anti-S Antibody Titre in Predicting Risk of Severe COVID-19.ISARIC 4C 死亡率评分、疫苗接种史和抗-S 抗体滴度在预测 COVID-19 重症风险中的作用。
Viruses. 2024 Oct 12;16(10):1604. doi: 10.3390/v16101604.
本文引用的文献
1
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后，SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
2
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.BNT162b2 mRNA COVID-19 疫苗加强针在预防以色列重症结局的有效性：一项观察性研究。
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
3
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
Zotero 插件